Are qualitative assessments of background parenchymal enhancement, amount of fibroglandular tissue on MR images, and mammographic density associated with breast cancer risk?

Radiology

Volumn 276, Issue 2, 2015, Pages 371-380

  Dontchos, Brian N ^a   Rahbar, Habib ^a   Partridge, Savannah C ^a   Korde, Larissa A ^a   Lam, Diana L ^a   Scheel, John R ^a   Peacock, Sue ^a   Lehman, Constance D ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BACKGROUND PARENCHYMAL ENHANCEMENT; BREAST CARCINOMA; BREAST DENSITY; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; CONDITIONAL LOGISTIC REGRESSION; CONTROLLED STUDY; FEMALE; FIBROGLANDULAR TISSUE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTRADUCTAL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; AGED; BREAST; BREAST NEOPLASMS; CONGENITAL MALFORMATION; EVALUATION STUDY; MAMMARY GLAND; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ADULT; AGED; BREAST; BREAST NEOPLASMS; CASE-CONTROL STUDIES; EVALUATION STUDIES AS TOPIC; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMARY GLANDS, HUMAN; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84938679552     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2015142304     Document Type: Article

References (27)

1. Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007;25(26):4104-4109.
2. Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW. Cancer screening in the United States, 2011: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2011;61(1):8-30.
3. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ 1999;319(7224):1562-1565.
4. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87(9):670-675.
5. Byrne C, Schairer C, Brinton LA, et al. Effects of mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes Control 2001;12(2):103-110.
6. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006;98(17):1204-1214.
7. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008;148(5):337-347.
8. D'Orsi CJ, Sickles EA, Mendelson EB, et al. ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. Reston, Va: American College of Radiology, 2013.
9. Wei J, Chan HP, Helvie MA, et al. Correlation between mammographic density and volumetric fibroglandular tissue estimated on breast MR images. Med Phys 2004;31(4):933-942.
10. Nie K, Chen JH, Chan S, et al. Development of a quantitative method for analysis of breast density based on three-dimensional breast MRI. Med Phys 2008;35(12):5253-5262.
11. Nie K, Chang D, Chen JH, Hsu CC, Nalcioglu O, Su MY. Quantitative analysis of breast parenchymal patterns using 3D fibroglandular tissues segmented based on MRI. Med Phys 2010;37(1):217-226.
12. Delille JP, Slanetz PJ, Yeh ED, Kopans DB, Garrido L. Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the T1 relaxation time of breast tissue. Breast J 2005;11(4):236-241.
13. Müller-Schimpfle M, Ohmenhaüser K, Stoll P, Dietz K, Claussen CD. Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 1997;203(1):145-149.
14. Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997;203(1):137-144.
15. Reichenbach JR, Przetak C, Klinger G, Kaiser WA. Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study. J Comput Assist Tomogr 1999;23(3):407-413.
16. Delille JP, Slanetz PJ, Yeh ED, Kopans DB, Halpern EF, Garrido L. Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging-initial observations. Radiology 2005;235(1):36-41.
17. King V, Kaplan J, Pike MC, et al. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging. Breast J 2012;18(6):527-534.
18. Schrading S, Schild H, Kühr M, Kuhl C. Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study. Radiology 2014;271(1):45-55.
19. Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 2002;4(5):197-201.
20. King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA. Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 2011;260(1):50-60.
21. American College of Radiology Breast MRI Accreditation Program. http://www.acr.org/Quality-Safety/Accreditation/Breast-MRI. Accessed July 14, 2014.
22. Giess CS, Yeh ED, Raza S, Birdwell RL. Background parenchymal enhancement at breast MR imaging: normal patterns, diagnostic challenges, and potential for false-positive and false-negative interpretation. RadioGraphics 2014;34(1):234-247.
23. Li J, Dershaw DD, Lee CH, Joo S, Morris EA. Breast MRI after conservation therapy: usual findings in routine follow-up examinations. AJR Am J Roentgenol 2010;195(3):799-807.
24. Passaperuma K, Warner E, Hill KA, Gunasekara A, Yaffe MJ. Is mammographic breast density a breast cancer risk factor in women with BRCA mutations? J Clin Oncol 2010;28(23):3779-3783.
25. Kerlikowske K, Hubbard RA, Miglioretti DL, et al. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med 2011;155(8):493-502.
26. Hansen NL, Kuhl CK, Barabasch A, Strobel K, Schrading S. Does MRI breast "density" (degree of background enhancement) correlate with mammographic breast density? J Magn Reson Imaging 2014;40(2):483-489.
27. Bhatelia K, Singh K, Singh R. TLRs: linking inflammation and breast cancer. Cell Signal 2014;26(11):2350-2357.